Brief: Cipla Says By CY 2026 Expect To Launch 4 Major Respiratory Assets
30/10/2025 07:43
Oct 30 (Reuters) - Cipla Ltd CIPL.NS: CIPLA - BY CY 2026 EXPECT TO LAUNCH 4 MAJOR RESPIRATORY ASSETS CIPLA - BY CY 2026 EXPECT TO LAUNCH GADVAIR, 3 PEPTIDE ASSETS, INCLUDING LIRAGLUTIDE Source text: ID:nBSEGTZF1 Further company coverage: CIPL.NS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cipla
See all newsFactbox: Global healthcare companies invest billions to boost US presence
Brief: Cipla, Qilu Pharmaceutical Partner For Licensing, Supply Of Biosimilar To Keytruda In US
India's Cipla, China's Qilu partner for US launch of Merck's Keytruda biosimilar
Brief: Cipla Enters Exclusive Partnership With Qilu For Keytruda Biosimilar In US
Brief: Cipla and SBP Group Sign Exclusive Licensing Agreement For HER2 Bispecific Antibody-Drug Conjugate